EGFR and prostate carcinoma: To confirm the cell-type specificity of BsAb-mediated targeting, we analyzed mRNA-LNP delivery to EGFR+ve (EGFR-positive), PSMA+ve (PSMA-positive) LNCaP prostate cancer cells (Figure 1F).